In the News

MSK researchers identified a protein called ZFP36L2 that acts as a critical "molecular switch" controlling how gut cells repair themselves after injury — a mechanism that colorectal cancer hijacks to spread to other organs. The findings could point toward new treatments that exploit cancer cells' dependence on this protein to stop metastasis or overcome treatment resistance.

MSK experts say blood tests are not the best way to detect colorectal cancer and instead recommend colonoscopy or a stool test for those who can’t have a colonoscopy.

New MSK research uncovers why some leukemia patients stop responding to promising new drugs; examines how bone’s hardness shapes the immune battle against metastasis; shows how a telehealth tobacco treatment program helps cancer patients quit smoking; creates the first atomic-level images of a key phosphate transporter that could inform treatment of ovarian cancer and kidney disease; finds Medicare Advantage patients with cancer receive optimal treatment at lower cost; and studies how much tissue surgeons should remove for tumor-related epilepsy.

Zidesamtinib, a new drug that treats non-small cell lung cancer carrying a mutation called a ROS1 fusion, has been approved by the FDA.

Learn how MSK is helping people with lung cancer driven by ROS1 fusions, thanks to continual improvements in specific targeted therapies.

Selpercatinib has received full FDA approval for treating tumors anywhere in the body that harbor a genetic change called a RET fusion.

Learn how a discovery about T cell exhaustion could lead to new ways to boost the effectiveness of immunotherapy.

A powerful therapy called an antibody-drug conjugate continues to provide lasting benefits for people with bladder cancer.

The FDA has approved zenocutuzumab (Bizengri®) for adults with advanced, unresectable, or metastatic cholangiocarcinoma driven by a molecular change called an NRG1 gene fusion, based on a trial led by an MSK investigator.

The final paper from the lab of the late MSK Developmental Biology Chair Kathryn Anderson reveals how a critical signaling molecule called WNT guides cells in the embryo from a state of high flexibility — known as "plasticity" — toward distinct, specialized identities. Completing it was a labor of love for her colleagues.